CEO of Harvard Bioscience Buys 5,000 Shares Post‑Split, Signaling Confidence in Volatile Market
Harvard Bioscience CEO’s 5,000‑share purchase signals confidence amid volatile markets, underscoring the firm’s proteomics tech potential and long‑term value.
2 minutes to read